Inspirion Wealth Advisors’s Phathom Pharmaceuticals PHAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$210K Hold
19,914
0.02% 177
2026
Q1
$221K Buy
19,914
+100
+0.5% +$1.26K 0.03% 156
2025
Q4
$329K Sell
19,814
-16,820
-46% -$240K 0.04% 129
2025
Q3
$662K Buy
36,634
+16,820
+85% +$174K 0.09% 85
2025
Q2
$190K Sell
19,814
-50
-0.3% -$277 0.03% 151
2025
Q1
$125K Sell
19,864
-100
-0.5% -$607 0.02% 152
2024
Q4
$144K Sell
19,964
-16,670
-46% -$206K 0.02% 146
2024
Q3
$662K Hold
36,634
0.09% 85
2024
Q2
$377K Buy
36,634
+1,500
+4% +$15.4K 0.06% 103
2024
Q1
$373K Hold
35,134
0.06% 106
2023
Q4
$322K Buy
35,134
+5,000
+17% +$43.1K 0.06% 106
2023
Q3
$312K Hold
30,134
0.06% 105
2023
Q2
$432K Buy
30,134
+6,885
+30% +$79.4K 0.08% 92
2023
Q1
$166K Sell
23,249
-20
-0.1% -$176 0.03% 138
2022
Q4
$261K Hold
23,269
0.06% 109
2022
Q3
$258K Hold
23,269
0.06% 103
2022
Q2
$196K Buy
+23,269
New +$239K 0.04% 116

Other funds holding PHAT

Inspirion Wealth Advisors's PHAT Position: Q2 2026 in Review

Inspirion Wealth Advisors held its Phathom Pharmaceuticals (PHAT) position steady in Q2 2026 at 19,914 shares worth $210K. The position accounts for 0.02% of the portfolio, ranked #177.

Inspirion Wealth Advisors first reported a position in PHAT in Q2 2022 and has held it in 17 quarters since. The position peaked at $662K in Q3 2025. 16 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Inspirion Wealth Advisors held 19,914 shares of Phathom Pharmaceuticals worth $210K as of Q2 2026.
  • Inspirion Wealth Advisors left its Phathom Pharmaceuticals share count unchanged in Q2 2026.
  • Phathom Pharmaceuticals made up 0.02% of Inspirion Wealth Advisors's portfolio in Q2 2026, its #177 holding.
  • Inspirion Wealth Advisors first reported a position in Phathom Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
  • Inspirion Wealth Advisors's Phathom Pharmaceuticals position peaked at $662K in Q3 2025.
  • 16 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Inspirion Wealth Advisors's 13F filing for Q2 2026, filed 7 Jul 2026.